JP Garnier’s seat isn’t cold yet and Andrew Witty won’t officially take over GSK until May 2008 – but already questions are being asked of the new man in a new blog andrewwitty.wordpress.com
The purpose of this blog is a call of conscience and compassion to Andrew Witty, the next CEO of GSK.
We all recognise the need for pharmaceutical drugs, and some can be life savers, but surely when a pharmaceutical company appears to harm more patients than it claims to help, then something must be done to rectify and address this? We also recognise the place of the pharmaceutical industry too, but has it become a greed fueled machine run amok with no regard for the efficacy or safety of new drugs? Is the safety and effectiveness of a medication paramount? Or does a loyalty to insatiable profits affect this?
Who is willing to tackle these issues? Where does the buck stop?
And where do honesty, transparency and good ethics begin?
Many hundreds of thousands of people have been adversely affected by GSK drugs, such as Avandia and Seroxat. GSK have had thousands of lawsuits over the years regarding these particular drugs and others in the past , drugs such as Selacryn, Lotronex and Myodil. Will the new GSK CEO address the issue of Seroxat (Paxil) Birth Defects, Suicide, Aggression, Addiction and Withdrawal? Or Avandia Causing Heart Attacks? Maybe Andrew Witty will be a different CEO than his predecessor?
Maybe he will put patients before profit?
One thing is for sure, GlaxoSmithKline definitely needs a radical change of its ethical policies.